GLP-1 specialist rides wave of interest toward Nasdaq listing

21 November 2023
carmot-large

Just six months after  raising $150 million in an upsized series E financing, cardiometabolic specialist Carmot Therapeutics has  filed for an initial public offering (IPO).

Founded in 2008, the company has attracted around $380 million in private investments since that time, while partnering with major players such as Gilead Sciences (Nasdaq: GILD), Amgen (Nasdaq: AMGN) and Roche (ROG: SIX) subsidiary Genentech.

With its focus on GLP-1 agonism, the Californian company could find itself at the epicenter of a revolution in the treatment of diabetes and obesity.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical